11 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2041
Next term end
5
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends May 2041 · High confidence
Also notable
Ends Oct 2042 · High confidence
Deuterated Tryptamine Derivatives and Methods of Use
US 11,242,318
The most cited patent in this portfolio, cited by 55 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2041.
Psilocybin Analogs, Salts, Compositions, and Methods of Use
US 12,735,386
Granted 2026. Too new for citation comparison; protection runs to 2042.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 15, 2027The maintenance fee for Deuterated Tryptamine Derivatives and Methods of Use (US 11,724,985) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Deuterated Tryptamine Derivatives and Methods of Use (US 11,746,088) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Deuterated Tryptamine Derivatives and Methods of Use (US 11,834,410) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Deuterated Tryptamine Derivatives and Methods of Use (US 11,958,807) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Deuterated Tryptamine Derivatives and Methods of Use | 7 in force | to May 2041 |
| Phenethylamine Derivatives, Compositions, and Methods of Use | 1 in force | to Mar 2043 |
| Psilocybin Analogs, Salts, Compositions, and Methods of Use | 1 in force | to Oct 2042 |
| Therapeutic Phenethylamine Compositions and Methods of Use | 1 in force | to Aug 2041 |
| Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods | 1 in force | to May 2041 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,242,318 | Deuterated Tryptamine Derivatives and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,724,985 | Deuterated Tryptamine Derivatives and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,746,088 | Deuterated Tryptamine Derivatives and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,834,410 | Deuterated Tryptamine Derivatives and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,958,807 | Deuterated Tryptamine Derivatives and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,110,272 | Deuterated Tryptamine Derivatives and Methods of Use In force · Low confidence | In force | Low confidence | |
| US 12,291,499 | Deuterated Tryptamine Derivatives and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,751,940 | Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods In force · High confidence | In force | High confidence | |
| US 12,122,741 | Therapeutic Phenethylamine Compositions and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,735,386 | Psilocybin Analogs, Salts, Compositions, and Methods of Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 1 patent in force now held by others · 23 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed